The company’s proprietary HALO™ platform technology supports the development of MET-233i, aiming to offer patients a more convenient dosing schedule with substantial weight loss.

In other recent news, Metsera Inc. has announced positive results from its Phase 1 clinical trial for MET-233i, an amylin analog aimed at treating obesity. The trial revealed up to an 8.4% mean ...

Boosting Quality of Weight Loss Combining bimagrumab ... Juvena Therapeutics, Kallyope, Metsera, Morphic Medic/GI Dynamics, Novartis, Novo Nordisk, Pfizer, ProSciento, Senda Biosciences, Skye ...

More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from weight-loss and ...

A cutting-edge mouse study reveals that tirzepatide, the dual GLP-1/GIP drug already hailed for impressive weight loss, does more than trim fat: it slashes the growth of obesity-linked breast tumors.

U.S.-based Kailera Therapeutics and Chinese firm Jiangsu Hengrui Pharmaceuticals' experimental weight-loss drug has helped overweight patients lose up to 17.7% of body weight in a late-stage study in ...

Researchers followed 60,000 adults aged 40 and older—who took various types of antidiabetic medication—for seven years ...

A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...

Pennsylvania Governor Josh Shapiro's office has said it is looking to change eligibility for weight loss drugs as part of its 2025-26 budget plans.

Viking Therapeutics's obesity/diabetes candidates and strong financials position it for success. Read here for an investment ...

Major insurance changes are coming for weight loss drugs. Here’s how it could affect patients ...

When it comes to weight loss, providers and patients argue that GLP-1 medications are not a one-for-one swap and that volatile insurance coverage contradicts the science and experience of people ...